X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The presentation will include clinical data demonstrating the robust improvements of function, long term pain, and joint structure by TPX-100 treatment, as well as the strong associations between the clinical and structural effects.
Lead Product(s): TPX-100
Therapeutic Area: Musculoskeletal Product Name: TPX-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
The presentation demonstrated clinically meaningful improvement of TPX-100 in overall knee pain and in specific key pain parameters in moderate to severe knee OA, linked to significant reductions in pathological bone shape change.
Lead Product(s): TPX-100
Therapeutic Area: Rheumatology Product Name: TPX-100
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
TPX-100-treated knees demonstrated clinically meaningful and statistically significant improvement in critical knee functions as compared to placebo-treated knees.
Lead Product(s): TPX-100
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
